| Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch-and hedgehog-dependent tumor-initiating cells J Domingo-Domenech, SJ Vidal, V Rodriguez-Bravo, M Castillo-Martin, ... Cancer cell 22 (3), 373-388, 2012 | 440 | 2012 |
| RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis JR Cortes, A Ambesi-Impiombato, L Couronné, SA Quinn, CS Kim, ... Cancer cell 33 (2), 259-273. e7, 2018 | 182 | 2018 |
| A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer Cancer Cell 27 (2), 223-239, 2015 | 164 | 2015 |
| Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas F Abate, AC da Silva-Almeida, S Zairis, J Robles-Valero, L Couronne, ... Proceedings of the National Academy of Sciences 114 (4), 764-769, 2017 | 121 | 2017 |
| Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL AA Wendorff, SA Quinn, M Rashkovan, CJ Madubata, ... Cancer discovery 9 (3), 436-451, 2019 | 63 | 2019 |
| GATA3-Controlled Nucleosome Eviction Drives MYC Enhancer Activity in T-cell Development and Leukemia L Belver, AY Yang, R Albero, D Herranz, FG Brundu, SA Quinn, ... Cancer discovery 9 (12), 1774-1791, 2019 | 32 | 2019 |
| Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer AK Biswas, S Han, Y Tai, W Ma, C Coker, SA Quinn, AR Shakri, TJ Zhong, ... Cancer discovery 12 (4), 1002-1021, 2022 | 27 | 2022 |
| FYN–TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma CS Moon, C Reglero, JR Cortes, SA Quinn, S Alvarez, J Zhao, WHW Lin, ... Nature cancer 2 (1), 98-113, 2021 | 22 | 2021 |
| The impact of economic recession on the incidence and treatment of cancer KY Ennis, MH Chen, GC Smith, AV D'Amico, Y Zhang, SA Quinn, ... Journal of Cancer 6 (8), 727, 2015 | 19 | 2015 |
| Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma JR Cortes, I Filip, R Albero, JA Patiño-Galindo, SA Quinn, WHW Lin, ... Cell reports 39 (3), 2022 | 17 | 2022 |
| Jak-STAT inhibition mediates romidepsin and mechlorethamine synergism in cutaneous T-cell lymphoma JR Cortes, CC Patrone, SA Quinn, Y Gu, M Sanchez-Martin, A Mackey, ... Journal of Investigative Dermatology 141 (12), 2908-2920. e7, 2021 | 17 | 2021 |
| The TINCR ubiquitin-like microprotein is a tumor suppressor in squamous cell carcinoma L Morgado-Palacin, JA Brown, TF Martinez, JM Garcia-Pedrero, ... Nature communications 14 (1), 1328, 2023 | 9 | 2023 |
| Phase I/II prospective trial of cancer-specific imaging using ultrasound spectrum analysis tissue-type imaging to guide dose-painting prostate brachytherapy RD Ennis, SA Quinn, F Trichter, S Ryemon, A Jain, K Saigal, ... Brachytherapy 14 (6), 801-808, 2015 | 8 | 2015 |
| Isolation of cancer stem cells from human prostate cancer samples SJ Vidal, SA Quinn, J de la Iglesia-Vicente, DM Bonal, V Rodriguez-Bravo, ... JoVE (Journal of Visualized Experiments), e51332, 2014 | 8 | 2014 |
| Epigenetic reversal of hematopoietic stem cell aging in Phf6-knockout mice AA Wendorff, SA Quinn, S Alvarez, JA Brown, M Biswas, T Gunning, ... Nature Aging 2, 1008–1023, 2022 | 3 | 2022 |
| Gene expression profiling of mechlorethamine and romidepsin combination shows downregulation of the JAK/STAT pathway in cutaneous T-cell lymphoma CC Patrone, M Sanchez-Martin, SA Quinn, M Frattini, A Ferrando, ... Journal of Investigative Dermatology 138 (5), S33-S33, 2018 | 1 | 2018 |
| Romidepsin and afatinib abrogate JAK-STAT signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma BB Shih, C Ma, JR Cortes, C Reglero, H Miller, SA Quinn, R Albero, ... Journal of Investigative Dermatology, 2024 | | 2024 |
| Microproteins and Epigenetic Remodeling in Cancer and Aging SA Quinn Columbia University, 2021 | | 2021 |
| VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas T Palomero, F Abate, AC da Silva Almeida, S Zairis, J Robles-Valero, ... Blood 128 (22), 2741, 2016 | | 2016 |
| Muddying the waters by overlooking treatment modality RD Ennis, SA Quinn Nature Reviews Clinical Oncology 11 (6), 305-307, 2014 | | 2014 |
